Daniel Havas

520 total citations
20 papers, 293 citations indexed

About

Daniel Havas is a scholar working on Physiology, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Daniel Havas has authored 20 papers receiving a total of 293 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Physiology, 7 papers in Molecular Biology and 6 papers in Cellular and Molecular Neuroscience. Recurrent topics in Daniel Havas's work include Alzheimer's disease research and treatments (12 papers), Parkinson's Disease Mechanisms and Treatments (5 papers) and Advanced MRI Techniques and Applications (4 papers). Daniel Havas is often cited by papers focused on Alzheimer's disease research and treatments (12 papers), Parkinson's Disease Mechanisms and Treatments (5 papers) and Advanced MRI Techniques and Applications (4 papers). Daniel Havas collaborates with scholars based in United States, Austria and Czechia. Daniel Havas's co-authors include Birgit Hutter‐Paier, Manfred Windisch, Stefanie Flunkert, Eliezer Masliah, Edward Rockenstein, Karl Crailsheim, Kiren Ubhi, Ernst Steyrer, Henri J. Huttunen and Dora M. Kovacs and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and International Journal of Molecular Sciences.

In The Last Decade

Daniel Havas

18 papers receiving 282 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Havas United States 11 151 83 76 71 44 20 293
Dustin Chernick United States 8 137 0.9× 58 0.7× 92 1.2× 53 0.7× 47 1.1× 10 341
Karin Breu Switzerland 5 192 1.3× 42 0.5× 94 1.2× 57 0.8× 55 1.3× 6 345
Julius N. Meißner Germany 4 251 1.7× 31 0.4× 93 1.2× 75 1.1× 125 2.8× 5 392
Annemieke A.M. Rensink Netherlands 7 249 1.6× 70 0.8× 132 1.7× 60 0.8× 88 2.0× 8 368
Katherine D. LaClair United States 6 124 0.8× 151 1.8× 151 2.0× 30 0.4× 52 1.2× 6 302
Tamao Tsukie Japan 11 224 1.5× 63 0.8× 184 2.4× 44 0.6× 47 1.1× 18 375
Anthony Caggiano United States 8 134 0.9× 29 0.3× 112 1.5× 82 1.2× 63 1.4× 15 357
Sandra O. Tomé Belgium 12 223 1.5× 158 1.9× 189 2.5× 108 1.5× 67 1.5× 22 464
N.J. Cairns United Kingdom 8 175 1.2× 44 0.5× 133 1.8× 51 0.7× 28 0.6× 13 265

Countries citing papers authored by Daniel Havas

Since Specialization
Citations

This map shows the geographic impact of Daniel Havas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Havas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Havas more than expected).

Fields of papers citing papers by Daniel Havas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Havas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Havas. The network helps show where Daniel Havas may publish in the future.

Co-authorship network of co-authors of Daniel Havas

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Havas. A scholar is included among the top collaborators of Daniel Havas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Havas. Daniel Havas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Querfurth, Henry, et al.. (2025). Target Validation Studies of PS48, a PDK-1 Allosteric Agonist, for the Treatment of Alzheimer’s Disease Phenotype in APP/PS1 Transgenic Mice. International Journal of Molecular Sciences. 26(8). 3473–3473.
2.
Čarná, Mária, Shanshan Wang, Daniel Havas, et al.. (2025). Developmental deletion of amyloid precursor protein precludes transcriptional and proteomic responses to brain injury. Alzheimer s & Dementia. 21(4). e70093–e70093.
3.
Devoto, Victorio M. Pozo, et al.. (2024). Swedish Alzheimer’s disease variant perturbs activity of retrograde molecular motors and causes widespread derangement of axonal transport pathways. Journal of Biological Chemistry. 300(4). 107137–107137. 1 indexed citations
4.
Foster, Kelly, Matteo Manca, Kim F. McClure, et al.. (2023). Preclinical characterization and IND‐enabling safety studies for PNT001, an antibody that recognizes cis‐pT231 tau. Alzheimer s & Dementia. 19(10). 4662–4674. 12 indexed citations
5.
Čaušević, Mirsada, Martina Pigoni, Alessio Colombo, et al.. (2018). BACE1-cleavage of Sez6 and Sez6L is elevated in Niemann-Pick type C disease mouse brains. PLoS ONE. 13(7). e0200344–e0200344. 13 indexed citations
6.
Pavlov, Pavel F., Birgit Hutter‐Paier, Daniel Havas, Manfred Windisch, & Bengt Winblad. (2018). Development of GMP‐1 a molecular chaperone network modulator protecting mitochondrial function and its assessment in fly and mice models of Alzheimer's disease. Journal of Cellular and Molecular Medicine. 22(7). 3464–3474. 9 indexed citations
7.
Collier, Timothy J., Kinshuk Raj Srivastava, Birgit Hutter‐Paier, et al.. (2017). Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form. Neurobiology of Disease. 106. 191–204. 26 indexed citations
8.
Krassnig, Stefanie, Nicole Taub, Daniel Havas, et al.. (2015). Influence of Lentiviral β-Synuclein Overexpression in the Hippocampus of a Transgenic Mouse Model of Alzheimer's Disease on Amyloid Precursor Protein Metabolism and Pathology. Neurodegenerative Diseases. 15(4). 243–257. 6 indexed citations
9.
Khairnar, Amit, Peter Latta, Eva Dražanová, et al.. (2015). Diffusion Kurtosis Imaging Detects Microstructural Alterations in Brain of α-Synuclein Overexpressing Transgenic Mouse Model of Parkinson’s Disease: A Pilot Study. Neurotoxicity Research. 28(4). 281–289. 15 indexed citations
10.
Khairnar, Amit, Jana Kučerová, Eva Dražanová, et al.. (2015). Late‐stage α‐synuclein accumulation in TNWT‐61 mouse model of Parkinson's disease detected by diffusion kurtosis imaging. Journal of Neurochemistry. 136(6). 1259–1269. 15 indexed citations
11.
Schmidt, Reinhold, Klaus Langer, Robert Wronski, et al.. (2014). Tracking of Magnetite Labeled Nanoparticles in the Rat Brain Using MRI. PLoS ONE. 9(3). e92068–e92068. 8 indexed citations
12.
Flunkert, Stefanie, et al.. (2014). Neuroinflammation and related neuropathologies in APPSL mice: further value of this in vivomodel of Alzheimer’s disease. Journal of Neuroinflammation. 11(1). 14 indexed citations
13.
Flunkert, Stefanie, Daniel Havas, Miklós Sántha, et al.. (2013). Impact of ApoB-100 expression on cognition and brain pathology in wild-type and hAPPsl mice. Neurobiology of Aging. 34(10). 2379–2388. 32 indexed citations
14.
Neddens, Joerg, Daniel Havas, Stefanie Flunkert, et al.. (2013). Time course and progression of wild type α-Synuclein accumulation in a transgenic mouse model. BMC Neuroscience. 14(1). 6–6. 31 indexed citations
15.
Paganetti, Paolo, Kavi Devraj, Nicolas Toni, et al.. (2013). Increased Efflux of Amyloid-β Peptides through the Blood-Brain Barrier by Muscarinic Acetylcholine Receptor Inhibition Reduces Pathological Phenotypes in Mouse Models of Brain Amyloidosis. Journal of Alzheimer s Disease. 38(4). 767–786. 9 indexed citations
16.
Nyborg, Andrew C., Jonathan R. Moll, Renee D. Wegrzyn, et al.. (2013). In Vivo and Ex Vivo Imaging of Amyloid-β Cascade Aggregates with a Pronucleon™ Peptide. Journal of Alzheimer s Disease. 34(4). 957–967. 10 indexed citations
17.
Havas, Daniel, Birgit Hutter‐Paier, Kiren Ubhi, et al.. (2011). A Longitudinal Study of Behavioral Deficits in an AβPP Transgenic Mouse Model of Alzheimer's Disease. Journal of Alzheimer s Disease. 25(2). 231–243. 40 indexed citations
18.
Huttunen, Henri J., Daniel Havas, Weiming Xia, et al.. (2010). The Acyl-Coenzyme A: Cholesterol Acyltransferase Inhibitor CI-1011 Reverses Diffuse Brain Amyloid Pathology in Aged Amyloid Precursor Protein Transgenic Mice. Journal of Neuropathology & Experimental Neurology. 69(8). 777–788. 46 indexed citations
19.
Schmidt, Reinhold, Daniel Havas, Stefan Ropele, Christian Enzinger, & Franz Fazekas. (2009). MRI in Dementia. Magnetic Resonance Imaging Clinics of North America. 18(1). 121–132. 1 indexed citations
20.
Schmidt, Reinhold, Daniel Havas, Stefan Ropele, Christian Enzinger, & Franz Fazekas. (2008). MRI in Dementia. Neurologic Clinics. 27(1). 221–236. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dustin Chernick Breakdown of academic impact, for papers by Karin Breu Breakdown of academic impact, for papers by Julius N. Meißner Breakdown of academic impact, for papers by Annemieke A.M. Rensink Breakdown of academic impact, for papers by Katherine D. LaClair Breakdown of academic impact, for papers by Tamao Tsukie Breakdown of academic impact, for papers by Anthony Caggiano Breakdown of academic impact, for papers by Sandra O. Tomé Breakdown of academic impact, for papers by N.J. Cairns
Rankless by CCL
2026